OmniAb, Inc. (OABIW) stock
OABIWNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as OABI
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 10/309% above fair value
$0.41−0.01 (-2.38%)
Close on Oct 30, 2026Market cap $742.95MP/E –Yield –
OmniAb ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
OmniAb's ebitda for the twelve months ending Dec 31, 2025 was -$47.22M. For fiscal 2025 it was -$47.22M. The highest annual figure on record is -$8.40M in fiscal 2022.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$47.22M | – |
| FY2024 | Dec 31, 2024 | -$50.92M | – |
| FY2023 | Dec 31, 2023 | -$49.92M | – |
| FY2022 | Dec 31, 2022 | -$8.40M | – |
| FY2021 | Dec 31, 2021 | -$19.36M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$8.06M | – |
| Q3 FY2025 | Sep 30, 2025 | -$13.49M | – |
| Q2 FY2025 | Jun 30, 2025 | -$11.57M | – |
| Q1 FY2025 | Mar 31, 2025 | -$14.10M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.27M | – |
| Q3 FY2024 | Sep 30, 2024 | -$14.84M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.20M | – |
| Q1 FY2024 | Mar 31, 2024 | -$17.60M | – |
| Q4 FY2023 | Dec 31, 2023 | -$16.27M | -217.3% |
| Q3 FY2023 | Sep 30, 2023 | -$15.47M | – |
| Q2 FY2023 | Jun 30, 2023 | -$14.59M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.59M | – |
| Q4 FY2022 | Dec 31, 2022 | $13.87M | – |
| Q3 FY2022 | Sep 30, 2022 | -$10.41M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.08M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.79M | – |